Study of Immune Responses in Healthy Adults Receiving the Oral Typhoid Vaccine Vivotif

What this Trial Is About

Researchers are conducting an open-label, non-randomized study to evaluate the immune response triggered by the oral typhoid vaccine, Vivotif. This vaccine has been approved by the FDA for travelers to developing countries. The study aims to improve understanding of the protective immune mechanisms activated systemically, which might also apply to other intestinal infections. Participants will receive four doses of the Vivotif oral typhoid vaccine, each given as one capsule on alternate days days 0, 2, 4, and 7 under supervision. After vaccination, blood, saliva, and stool samples will be collected during follow-up visits lasting up to eight years to monitor immune responses. During the study, volunteers will provide specimens for laboratory analysis to measure the percentage of responders approximately five years after vaccination. The research includes regular health screenings and monitoring to ensure participant safety. The total involvement may last up to eight years, allowing for long-term observation of the vaccines immunological effects.

Blood Donor CVD 5000